Abstract LB095: Hybrid TCR-CAR design surpasses conventional CARs and patient-derived TCRs in targeting an ultra-low-density neoantigen
Brian J. Mog(Howard Hughes Medical Institute), Shibin Zhou(Cancer Genetics (United States)), Evangeline Watson(Howard Hughes Medical Institute), Jacqueline Douglass(Howard Hughes Medical Institute), Sarah R. DiNapoli(Howard Hughes Medical Institute), Alexander H. Pearlman(Johns Hopkins University), Jiaxin Ge(Howard Hughes Medical Institute), Nickolas Papadopoulos(Johns Hopkins University), Maximilian F. Konig(Johns Hopkins Medicine), Katharine M. Wright(Johns Hopkins University), Suman Paul(Johns Hopkins University), Nikita Marcou(Howard Hughes Medical Institute), Stephanie Glavaris(Sidney Kimmel Comprehensive Cancer Center), Drew M. Pardoll(Bloomberg (United States)), Sandra B. Gabelli(Johns Hopkins University), Michael S. Hwang(Howard Hughes Medical Institute), Tushar D. Nichakawade(Howard Hughes Medical Institute), Chetan Bettegowda(Johns Hopkins University), Bert Vogelstein(Howard Hughes Medical Institute), Michelle S. Miller(Howard Hughes Medical Institute), Nicolas Wyhs(Johns Hopkins University), Emily Han-Chung Hsiue(Howard Hughes Medical Institute), Kenneth W. Kinzler(Johns Hopkins University), P. Aitana Azurmendi(Howard Hughes Medical Institute)
Cited by 1
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k